SSW
CORT icon

Smith Shellnut Wilson’s Corcept Therapeutics CORT Stock Holding History

Smith Shellnut Wilson’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$401K Hold
4,819
– – 0.15% 90
2025
Q2 		$354K Hold
4,819
– – 0.15% 92
2025
Q1 		$550K Hold
4,819
– – 0.25% 67
2024
Q4 		$243K Hold
4,819
– – 0.11% 129
2024
Q3 		$223K Buy
+4,819
New +$171K 0.1% 137

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Smith Shellnut Wilson's CORT Position: Q3 2025 in Review

Smith Shellnut Wilson held its Corcept Therapeutics (CORT) position steady in Q3 2025 at 4,819 shares worth $401K. The position accounts for 0.15% of the portfolio, ranked #90.

Smith Shellnut Wilson first reported a position in CORT in Q3 2024 and has held it in 5 quarters since. The position peaked at $550K in Q1 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Smith Shellnut Wilson held 4,819 shares of Corcept Therapeutics worth $401K as of Q3 2025.
  • Smith Shellnut Wilson left its Corcept Therapeutics share count unchanged in Q3 2025.
  • Corcept Therapeutics made up 0.15% of Smith Shellnut Wilson's portfolio in Q3 2025, its #90 holding.
  • Smith Shellnut Wilson first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Smith Shellnut Wilson's Corcept Therapeutics position peaked at $550K in Q1 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Smith Shellnut Wilson's 13F filing for Q3 2025, filed 27 Oct 2025.